Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …

Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and development of tyrosine kinase inhibitors (TKIs) of EGFR have achieved a paradigm …

Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …

As the first approved epidermal growth factor receptor (EGFR)-targeted therapy for nonsmall
cell lung cancer (NSCLC), the clinical development of gefitinib was complex. Advances in …

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …

Treatment outcome for advanced-stage non-small cell lung cancer (NSCLC) is limited by
empiric administration of cytotoxic chemotherapy. Recent advances in molecular genomics …

Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) is
involved in tumor development and progression in non-small-cell lung cancer (NSCLC) …

Abstract A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …

Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …